Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/bloodadvances.2025016037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Venous Thromboembolism Therapy with Edoxaban in Daily Care Patients: Results from the DRESDEN NOAC REGISTRY.
TH Open
July 2025
Division Hematology, Department of Medicine I, Thrombosis Research Unit, University Hospital "Carl Gustav Carus" Dresden, Dresden, Germany.
Direct oral anticoagulants such as edoxaban are standard of care in current treatment of venous thromboembolism (VTE). However, phase III trial data need confirmation in real-world settings. We extracted data from the prospective, noninterventional multiple-indication DRESDEN NOAC REGISTRY to evaluate outcome rates during VTE treatment with edoxaban.
View Article and Find Full Text PDFDose-Reduced Apixaban for Secondary Prophylaxis in Severely Obese Patients: A Single Center Analysis.
Blood Adv
July 2025
Montefiore Medical Center/Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, United States.
Primary Care Clinicians' Prescribing Patterns of Reduced-Dose Direct Oral Anticoagulants for Extended-Phase Venous Thromboembolism Treatment.
J Clin Med
December 2023
Department of Medicine, Intermountain Medical Center, Murray UT 84107, USA.
Article Synopsis
- The study focused on understanding how primary care clinicians prescribe direct anticoagulants (DOACs) like apixaban and rivaroxaban for the extended treatment of venous thromboembolism (VTE) and their dose reduction practices.
- A survey was conducted with 227 clinicians to analyze their prescribing patterns, revealing that most (59%) used dose reduction, with hospitalists and early-career clinicians being the least likely to do so.
- The research identified five distinct prescribing behavior clusters based on dose reduction frequency and clinician characteristics, suggesting areas for targeted interventions to improve anticoagulant management.
Safety and mortality outcomes for direct oral anticoagulants in renal transplant recipients.
PLoS One
May 2023
Department of Nephrology, Mayo Clinic, Scottsdale, AZ, United States of America.
Purpose: Direct oral anticoagulants (DOACs) are increasingly used in renal transplant recipients (RTR), but relatively understudied in this population. We assess the safety of post-transplant anticoagulation with DOACs compared to warfarin.
Methods: We conducted a retrospective study of RTRs at the Mayo Clinic sites (2011-present) that were anticoagulated for greater than 3 months excluding the 1st month post-transplant.
Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
J Thromb Thrombolysis
April 2023
Department of Public Health and Clinical Medicine, Umeå University, Sundsvall, Sweden.
Direct oral anticoagulants (DOACs) used in nonvalvular atrial fibrillation (NVAF) are dose-reduced in elderly and patients with impaired renal function. Only reduced dose dabigatran is concluded as having similar stroke risk reduction and lower risk of major bleeding than warfarin in the pivotal studies. In clinical practice, reduced dose is prescribed more often than expected making this an important issue.
View Article and Find Full Text PDF